// App-Quantinova.ai

332 : A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Researchers

Presenter

  • Jesus G. Berdeja

Principal Investigators

  • Ruben Niesvizky

  • Jianchang Lin

  • Alessandra Di Bacco

  • Neeraj Gupta

  • Ai-Min Hui

  • Paul G. Richardson

  • Sagar Lonial

  • Mehdi Hamadani

  • A. Keith Stewart

  • Vivek Roy

  • Parameswaran Hari

  • Robert Vescio

  • Deborah Berg

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

Disease

  • Peripheral neuropathy

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Deep vein thrombosis

  • Multiple Myeloma

  • Renal disease

  • Venous thrombosis

  • Gastrointestinal bleeding

  • Syncope

Biomarkers

  • Cluster of Differentiation 34

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • double blind/blinded

  • fixed dose

Phase

  • I/II

Study Id's

  • NCT01217957

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved